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Next-generation sequencing (NGS) technologies have begun to revolutionize the ﬁeld of haematological
malignancies through the assessment of a patient's genetic makeup with a minimal cost. Signiﬁcant
discoveries have already provided a unique insight into disease initiation, risk stratiﬁcation and thera-
peutic intervention. Sequencing analysis will likely form part of the routine diagnostic testing in the
future. However, a number of important issues need to be addressed for that to become a reality with
regard to result interpretation, laboratory workﬂow, data storage and ethical issues. In this review we
summarize the contribution that NGS has already made to the ﬁeld of haematological malignancies.
Finally, we discuss the challenges that NGS technologies will bring in relation to data storage, ethical and
legal issues and laboratory validation. Despite these challenges, we predict that high-throughput DNA
sequencing will redeﬁne haematological malignancies based on individualized genomic analysis.
Copyright © 2015 Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The completion of the human genome sequence project heralded a new era of medical and genetic research. With the publication of the
draft genome in 2001 and the completion of the euchromatic sequence in 2004, the true potential of genetic research was realised [1e3].
Clinicians began to see personalised medicine as the future of hospitals and researchers seen the potential for discovery and better un-
derstanding of many diseases [4]. The technique which made this new era a reality was Sanger Sequencing, developed in the late 70s by
Frederick Sanger and his team [5]. This technique was the crux of the Human Genome Project, securing Sanger sequencing's place in
laboratories across the globe as the “Gold Standard” method for validation, research, and diagnostics for the past three decades.
Research began in earnest into the Human Genome for discovery of new biomarkers, pathways of disease and inherited genes. However,
discoveries did not come as fast as many presumed. The main limiting step for the advancement in research was that of Sanger sequencing
itself due to its expense, low throughput, large fragment requirements and time intensive protocols [6]. Despite being the driving force of
many major discoveries and projects, it could not keep up with the ever increasing demands of researchers and clinicians, with its lack of
multiplexing, limit of fragment sizes, and painstaking repetitiveness, many researchers began asking for a new, improved sequencing
paradigms [7].
Several techniques began to appear such as sequencing by hybridization, parallel signature sequencing and pyrosequencing to name a
few [8e10]. These three methods addressed the need for shorter fragments, multiplexing, larger throughput and higher sensitivity, but it
was pyrosequencing which was to become the ﬁrst of the Next Generation of sequencers with the release of the 454 system by 454/Roche in
2005 [11]. This opened the ﬂoodgates for more next generation sequencers with several platforms entering the market in a relatively short
period of time. Each of these machines shared similar performance on throughput, accuracy and cost in comparison to Sanger and so after
the success of these initial platforms, new machines and techniques were rapidly developed to keep up with the demands of research
laboratories [12e15]. With rapid improvements in sequencing methods, several of the initial techniques used have already been superseded
with simpler, more accurate techniques [16], but in an ever developing ﬁeld, no technique remains the same for long.aematology Department, Belfast Health and Social Care Trust, 51 Lisburn Road, Belfast, BT9 7AB, UK.
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importance of the underlying genetics of many diseases. One such ﬁeld that has beneﬁtted greatly from this is that of haematological
malignancies. Next generation sequencing has made large advancements in the understanding of the underlying mechanisms of several
haematological cancers over the last 10 years which would not have been possible with previous investigative techniques [17,18] (Fig. 1).
1.1. The next generation
Multiple platforms have been released over the past 8 years which have opened the doors to high throughput, high sensitivity, quick
whole genome sequencing. Each platform offers various sequencing approaches, such as whole genome sequencing (WGS), whole exome
sequencing (WES), amplicon sequencing to name a few, alongside their own advantages and disadvantages and so a decision on which
platform to ultimately go with is down to the needs of the researcher and the data produced, namely transcriptomics, genomics, and
epigenomics [17,19]. Due to the large number of platforms currently available, below is a table constructed to compare the most popular
models available based on their accuracy, method of sequencing and other criteria (Table 1). For those wishing for a more in depth
knowledge of the platforms, please see reviews [11,14,15,19,20].
Two of the most common sequencing approaches taken are that of Whole Genome Sequencing (WGS) and Whole Exome Sequencing
(WES). Both are very powerful methods but both carry their own beneﬁts and pitfalls. One such studywhich beneﬁted fromWGSwas that of
sequencing the Acute Myeloid Leukaemia (AML) genomewhich allowed for the discovery of new candidate genes which were associated in
the pathogenesis of this disease [25] however, the massive amounts of data produced from this level of sequencing proved to be almost
impossible to analyse in a reasonable amount of time leading to only 2% of the genome being used for validation [26].WESwould prove to be
a good answer to this colossal data problem however in doing this, ~98% of the genome will be excluded from sequencing which could in
turn eliminate important genetic discoveries after the ﬁndings of the Encyclopedia of DNA Elements group who have reported that >80% of
the genome is biochemically active [27].
Another increasingly popular sequencingmethod is that of amplicon sequencing, a techniquewhich selectively enriches chosen genomic
areas of interest for sequencing [28]. This is a good alternative to the massive data outputs of whole genomes which can run into the 90
gigabyte territory with deep sequencing making analysis a major problem and also introduces data storage issues. Amplicon sequencing in
comparison toWES andWGS requiresmuch less DNA, involves only one PCR reaction saving time, it is alsomore cost effective thatWGS and
WES if you wish to look at only a particular region of interest. Another major advantage is that this has allowed sequencing to occur in
smaller laboratories due to the minimal requirements for this method over WGS/WES but as with every technique, there are disadvantages
such as time required for library preparation, and with the ever decreasing costs of WGS there will come a point where this method is no
longer ﬁnancially feasible.
1.2. Impact on haematological malignancy research
Research in this ﬁeld developed with the introduction of cytogenetics in the 1960s allowing for the discovery of important chromosomal
translocations in Chronic Myeloid Leukaemia (CML) and Acute Myeloid Leukaemia (AML) such as that of the infamous PhiladelphiaFig. 1. Timeline of genetic discoveries.
Table 1
Summary of commonly used sequencing platforms.
Platform Sequencing Ampliﬁcation Read length Data output Run time Accuracy
Roche 454 GS Junior Sequencing by synthesis  pyrosequencing emPCR 400 bp 35 Megabases 10 h 99%
Illumina HiSeq 2000 Synthesis by sequencing e reverse dye terminator Bridge PCR 36e101 bp 300 Gigabytes 2.5e11 days 90e99.9%
Illumina MiSeq Synthesis by sequencing e reverse dye terminator Bridge PCR 36e151 bp >1 Gigabyte 4e27 h 75e90%
Life Technologies Ion
Torrent
Synthesis by sequencing e hydrogen ion detection emPCR Dependent on
chip size e >100bp
>1 Gigabyte 2 h> 99%
NB: All information derived from platform websites [21e24].
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helped evolve our understanding of the underlying mechanisms of haematological cancer. As NGS technologies became commercially
available during the mid-2000s, there was a sudden inﬂation in the rate of major discoveries due to the increased sensitivity of NGS as well
as a better understanding of the importance of the genetics of these conditions which led to as many breakthroughs in the last 10 years as
there has been in the previous 30 years [17]. (Fig. 1)
As NGS importance has become more profound, and with its associated costs dropping exponentially each year, larger and more
encompassing studies have begun into haematological cancers to unearth new pathways and biomarkers, to enhance our understanding of
its development as well as provide new diagnostic and treatable markers for translation into the clinic to improve patient care and survival.
1.3. Acute Myeloid Leukaemia (AML)
One of the most compelling studies showcasing the need for NGS is that of the WGS of AML, the most common myeloid malignancy in
adults [25,26]. The tumour genome of a patient presenting with the most common subtype, French-American British (FAB) M1, of AMLwith
normal cytogenetics was sequenced, alongside the patient's normal skin cells to provide an unbiased portrait of the mutations present
within the tumour in 2008. Both genomes were sequenced with a high degree of coverage (32.7 fold tumour genome, 13.9 skin genome)
[25]. The results obtained revealed 10 mutated genes of which 2 are previously described and 8 newly discovered; CDH24, PCLKC/PCDH24,
GPR123, EBI2/GPR183, PTPRT, KNDC1, SLC15A1, and GRINL1B were novel.
Due to themassive data handling associatedwithWGS studies, the data selected for further analysis was deﬁned by comparing the single
nucleotide variants (SNVs) within the tumour and skin genomes which showed 97.6% of the SNVs were present in both genomes, leaving
2.4% for further investigationwhere the 10 describedmutations were found. This study highlighted NGS as a powerful tool for the discovery
of novel mutations for future study as biomarkers and therapeutic targets as within the previous two decades little had changed in the
therapy of AML due to the lack of understanding of its genetic pathogenesis.
In 2009, a study using similar data eliminationmethods on a different patient with the same AML subtype uncovered recurrent IDH1 and
IDH2 mutations, a gene encoding isocitrate dehydrogenase 1, which were previously only reported in gliomas [32,33]. IDH1 is a suggested
tumour suppressor gene which is inactivated by dominant mutations of Arginine 132 (R132) [34] . IDH1mutations were found in up to 50%
of AML patients which further strengthened the support for NGS as a mutation discovery tool. Another ﬁnding of this study was that the
mutations found in the AML tumours were in different frequencies than that found in glioblastoma samples; R132Cmutations were present
in 50% of AML samples in comparison to 4% of gliomas. Further studies showed these mutations to be present in high occurrence in
intermediate-risk AML cytogenetic proﬁles and associated with a poor prognosis [35].
Ley and his team re-sequenced the genome of their cytogenetically normal AML M1 patient in their seminal 2008 paper using advanced
NGS technology providing deeper sequencing coverage [25]. Mutations within the DNMT3A gene, encoding DNA methyltransferases, were
subsequently discovered resulting in the further study of 188 normal matched AML tumours to ﬁnd that was a frequently occurring event
associated with poor prognosis. Relationships between DNMT3A mutations as other commonly mutated genes within AML were also
resolved showing FLT3, NPM1 and IDH1 mutations were signiﬁcantly enriched in the presence of this mutation.
A recent study carried out in 2012 identiﬁed 9mutationswhichwere already present in haematopoietic cells which required an initiating
event to drive oncogenesis; an unusual discovery as in many cancers, it is thought a key event creates these mutations [36]. This study was
carried out onM1 andM3AML subtypes and provided interesting results showing DNMT3A, NPM1, IDH1, and TET2weremutations unique to
M1 genomes and occur rarely in M3 indicating different initiating mutation events for each subtype. There was also evidence of shared
initiation mutations through FLT3 ITD which is present in both subtypes.
Another major discovery which deserves mentioning involving NGS and AML is that of clonal evolution pathways in relapsed AML
patients and associated novel mutations [37], which further shows NGSs potential in the understanding of the underlying mutations and
pathways in this highly complex disease.
1.4. Myelodysplasia
Splicing machinery defects were a prevalent discovery using WES in this condition with evidence of six novel RNA splicing machinery
genes containing mutations affecting the 3’-splice site recognition in pre-mRNA processing [38]. Major effects of this are impaired hae-
matopoiesis and dysfunctional mRNA splicing which were found to be caused by the following 6 genes; PRPF40B, U2AF35, SRSF2, ZRSR2,
SF3A1, and SF3B1. These were also found to be mutually exclusive of one another and, depending on disease subtype, occurring in different
frequencies.U2AF2 and SF1mutations hold some signiﬁcance as being exclusively found inmyelodysplastic syndromes [39]. Mutationswere
associated in only 44% of cases with increased sideroblasts and up to 88% of cases with minimal sideroblasts. This was the ﬁrst indication
that mutations resulting in changes to the splicing machinery could play a role in human pathogenesis.
The results of this study were further substantiated several months later revealing the importance of a spliceosomal subunit SF3B1, part
of the small nuclear ribonucleoprotein (snRNP), as a recurrently mutated gene of a frequency of ~20% within patients of myeleodysplastic
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peripheral blood samples providing a potential biomarker for future use within the clinic.
1.5. Chronic lymphocytic leukaemia (CLL)
As is the case for many haematological malignancies, the molecular pathogenesis of CLL, a common clinically heterogeneous cancer,
remained largely unknown until a novel study approach combining NGSWES and Copy Number Analysis was able to shed some light on the
mutations driving this disease [41]. This study found 32 genes to be associated with the initiation of CLL however, a novel gene, NOTCH1, was
the focus for further study as it was found to be present in 8.3% of the CLL cases at diagnosis. Although previously reported in various studies,
the frequency of this mutation of the transmembrane protein gene family was considered to be a rare event [42]. As the disease progressed
to a more aggressive form and Richter's Transformation, this frequency increased to 31.0% providing a diagnostic predictor of prognosis for
clinicians at presentation of CLL.
Further studies on the NOTCH1 gene provided evidence of functional relevance of this mutation in CLL, alongside another mutation as
oncogenic activating events [43]. Initial WGS on 4 patients with CLL provided 46 somatic mutations whichmay affect gene function; this led
to a cohort of 363 CLL tumours being sequenced to discover 4 frequently mutated genes: NOTCH1, XPO1, MYD88, and KLHL6. MYD88, a
myeloid differentiation primary response gene, plays a role in the signalling pathways of the immune response as well as being implicated in
lymphomas, promoting the view of the relevance of this mutation in lymphoid neoplasms [44]. An associationwith lower age of diagnosis is
linked with this mutation. This study successfully highlights the functional relevance of these two mutations for the formation of a
favourable environment for the survival of CLL cells as well as adverse clinical outcome. Not only were potential treatable targets revealed,
but also new factors to take into consideration in the clinic for diagnosis and prognosis.
With the importance of splicing machinery defects becoming clear in studies for myeloid neoplasms, the discovery of these mutations in
CLL came in 2012. WES of a group of 105 CLL tumours revealed 78 genes with potential function altering mutations [45]. Of these genes,
SF3B1 was mutated in 9.7% of cases which was coupled with poor clinical outcome, faster disease progression and low survival rates in
affected individuals. This paper also substantiated the discovery of NOTCH1 as a recurrently mutated gene in CLL [43,44] as well as rein-
forcing the notion of targeting the mRNA splicing pathway for treatment. The importance of SF3B1 as a clinically relevant gene became
apparent with its relationship with aggressive disease progression, the opposite of ﬁndings in myelodysplastic syndromes, as well as being
an independent prognostic factor [40,46].
Other novel mutations have been found including ZMYM3, FBXW7, MAPK1 and DDX3X in work carried out in 2011 showing their
interactionwith the commonly mutated CLL genes NOTCH1, SF3B1 andMYD88 [47]. Nine genes in total, including previously identiﬁed TP53,
ATM andMYD88 genes, were identiﬁed as being driver mutations in the oncogenesis of CLL, supported by their frequency in conserved sites
as well as showing functional importance. This study was unusual in its design as rather than several genomes being sequenced for
detection of potential somatic mutations for further analysis in expanded cohorts, the approach of WGS and WES of a large set of patients
(91 in total) was taken to increase the probability of discovering a much broader range of mutations to give a better picture of the path-
ogenesis of this disease.
The importance of SF3B1 and NOTCH1 mutations were not overlooked with a clinical trial of 494 patients analysed for their mutational
status of these genes and then monitored in relation to these for treatment response, survival and biological variables [48]. The ﬁndings
supported previous suggestion of clinical relevance with NOTCH1 patients (10% overall) having reduced, progression free survival and SF3B1
patients (17% overall) having shorter overall survival and no associated TP53 mutations. TP53 was still the most informative mutation as
indicator of poor survival [49] however NOTCH1 and SF3B1 were still added sources of information as independent prognostic markers for
shorter survival.
1.6. Other haematological malignancies
One leukaemia with poor survival is a relapsed paediatric patient with an Acute Lymphocytic Leukaemia which has a 30% survival rate.
Clinical and biological differences between diagnosed and relapsed cells were well established however the molecular trigger for relapse
remained unknown until a study of Copy Number Analysis (CNA) on 61 diagnosis-relapse matched paediatric cases was carried out [50]. B-
ALL and T-ALL cases were included in this study showing amajority of relapsed cases (88.5%) contained CNAs present at diagnosis leading to
the conclusion that the CNAs responsible for relapse are present at diagnosis in small clone quantities and are also therapeutically immune.
Potential pathways were identiﬁed for these CNAs including the previously deﬁned ETV6-RUNX1 pathway present at both diagnosis and
relapse [51] as a potential treatment candidate. Other ﬁndings in this paper showed the complexity of CNA changes between diagnosed and
relapsed samples which will require further research.
Good understanding of several of the translocations andmutations causing structural aberrations in the subgroups of Diffuse Large B-Cell
Lymphoma (DLBCL) were well known but the genetic lesions responsible for malignant transformation remained unclear. Combined WES
and CNA techniques revealed a number of previously unrecognised pathways and mutations in this malignancy [52]. The main aim of this
study was to characterise the complexity of the DLBCL genome but other interesting ﬁndings were that of unknown alterations to the TNF
AIP3 tumour suppressing gene and a translocation between CDKN2A-CDKN2B. The main ﬁnding of this study is the mutations of the MLL2
gene encoding for a trimethyltranferase. This gene with a well-known inﬂuence over other genes has a suggested role as a haploinsufﬁcient
tumour suppressor and so that abnormalities inMLL2 could trigger an oncogenic event within DLCBL, this claim is further substantiated by
the role of MLL2 in the pathogenesis of acute leukaemia and other cancers [53e55].
Whole exome sequencing of Hairy Cell Leukaemia (HCL) tumour cells with matched normal cells from a patient showed previously
undiscovered BRAF mutations, further strengthening the argument for the increased sensitivity of NGS [56]. As with many other haema-
tological malignancies, the clinco-pathological features of this disease were well characterized however its underlying development was
poorly understood until the discovery of recurrent BRAF V600Emutations in all patients. Further studies showed thismutation to be targeted
by PLX-4720, a small inhibitor molecule, which provided strong evidence for further research of the pathogenesis of HCL, diagnosis and
development of targeted therapeutics. Further research conducted by Dietrich and his team [57], conﬁrmed these ﬁndings as well as
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as splenic marginal zone lymphoma.
Finally, a WES study into the genetics of T-Cell Large Granular Lymphocytic Leukaemia provided evidence of STAT3mutations in 40% (31
of 77) of cases, indicating this mutation is the underlying cause of the pathogenesis of this cancer [58]. Aside from aberrant STATs signalling,
further hotspots were found in exon 21 of the 31 STAT3mutant positive cases, an area where dimerization and activation of the STAT protein
occurs, indicates this exon could provide information on the development of this disease.
Taking all of these diverse studies together, the impact of NGS technologies on the deciphering of haematological malignancies has been
profound, with a greater understanding of the development of these disease found within the last six years than there has been in the last
two decades. The discoveries discussed here are just a small snapshot of the power this technology has in cancer research.
1.7. Clinical relevance of NGS
As outlined, the developments within haematological cancer research have been signiﬁcant from the introduction of NGS with dis-
coveries coming much faster than before and the understanding of this group of diseases becoming clearer with each mutation detected.
Clinicians are now seeing the beneﬁts of genetic based detection for both diagnosis and treatment but the question remains as to whether
this is a feasible technique or do the current tests already do what is required? Can NGS transit from a discovery tool in haematological
malignancies to a cost-effective molecular diagnostic tool?
Most diagnostic tests for haematological malignancies were immunologically, cytogenetically, and PCR based. Cytogenetics was a
particularly powerful tool for gaining prognostic information and ﬂow cytometry alongside immunocytochemistry for detection of aber-
rantly expressed proteins [59]. However, with the introduction of PCR for detection of translocations, microsatellites, clonality and muta-
tional analysis; it became an increasingly useful tool in the diagnostic laboratory [60]. Sanger sequencing is currently considered the “Gold
Standard” of mutational analysis in diagnostics and has been for the past three decades, routinely sequencing for the status of KRAS, NRAS,
EGFR and BRAF within multiple cancers however, its low throughput, high cost, low sensitivity and slow result turnaround are no longer
suitable for diagnostics with our increased understanding of genetics in cancer and hence the need for more sensitive, faster, cheaper
techniques [61,62].
As outlined in a study of NGS in a clinical diagnostic setting, massively parallel sequencing is a feasible option for future diagnostics with
its low cost, high throughput, high sensitivity, minimal DNA input and range of information to be gained from results such as mutational
status, translocation information and analysis of multiple genes or hotspots in one experiment [63]. The ability to barcode samples with
Multiplex Identiﬁers (MIDs) also allows for multiple patients to be sequenced at once which is a key need for a diagnostic laboratory.
Another beneﬁt of NGS is the ability to detect multiple abnormalities such as point mutations, insertions, deletions and chromosomal
rearrangements using a single sequencing run [64], an ability not currently available through any other test. In a novel approach Bouamar
and colleagues used a capture based analysis for the identiﬁcation of IGH rearrangements in a series of DLBCL (REF). In this series they
conﬁrmed the presence of know fusions and discovered novel IGH partners in DLBCL. Whilst this was performed only on fresh frozen
material it is envisaged this will be applicable to FFPE material [65].
A major advantage of this technology is its sensitivity as Sanger sequencing has difﬁculties in detecting mutations which occur lower
than around 10% in tumours [66]. One study was able to detect low levels of TP53 mutations, with a clone size of 11% in 20% of patients with
early low risk MDS allowing for better follow up of these patients who now present a risk of increased leukaemic evolution [67].
With its high throughput, sensitivity, speed, cost and information capabilities, the future of NGS as a clinical tool is strong and is likely to
replace current diagnostic standards such as Sanger sequencing however, there are still several hurdles for this technology to cross before
this goal can be realised.
1.8. Challenges of NGS technologies
With all the advantages and potential NGS brings to research and diagnostics, it also has several pitfalls which need to be addressed.
The ﬁrst problem encountered in developing NGS for diagnostics was that of the massive amounts of data produced fromWGS andWES,
most of whichwould not be relevant in a diagnostic setting where information from a particular gene of interest is sufﬁcient. One such study
which is addressing this problem is that of the Interlaboratory Robustness of next generation sequencing consortium (IRON). This group is
designing diagnostically suitable deep sequencing amplicon assays which will provide information on disease classiﬁcation, patient
stratiﬁcation, and allow for monitoring of a patient's minimal residual disease from a sequencing run for various haematological cancers
[68]. These assays are composed of multiple clinically and diagnostically relevant genes and hotspots of interest within each cancer to give
this range of information. Asmentioned before, MIDs are used in these assays to allow formultiple patients to be screened at once. Amplicon
assays such as this allow for quick gain of relevant information without the need for in depth bioinformatics analysis.
Other challenges faced are that of the costs associated with gaining the equipment, software and consumables required for NGS. Current
estimates of the start-up capital required are around $500,000 (~£300,000) [69] but this can be offset by the cost per base of sequencing
where Sanger is more expensive and a much larger data output is also achieved.
In terms of data output, another problem is encountered through analysis and storage of this data. The amount of data produced per
sequencing run on NGS platforms runs into the gigabytes, which will require specialist high power computers to allow for quick, effective
processing and analysis of this level of data. One such suggestion to remedy this is the use of cloud computing to create a galaxy-based
analysis pipeline to detect mutations [70]. The computing infrastructure required to carry out NGS is also a large demand requiring a
minimum of an 8 quad core, 32 gig RAM, 10 terabyte hard disk computer. In order to set up and maintain such an infrastructure will also
require qualiﬁed ICT and bioinformaticians which can immediately out price some research and diagnostic facilities [71]. However, with
computers becoming more prevalent in the everyday lives of researchers, newly graduated scientists are equipped with the knowledge
required to carry out maintenance and repair of most computer problems.
Amajor area of concernwithin NGS is that of ethical and legal issues. WithWGS being able to give an unbiased overview of a person's full
genome, known cancer/disease driving genes can be seen as well as their potential to develop and this information could then be shared to
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through making it illegal to pass genetic information onto insurance companies or potential employers to ensure no genetic discrimination
can take place [71]. Alongside this, the conundrum of deciding to tell a patient what potential disease causing genes they have is still a highly
debated issue. There have been detailed discussion amongst researchers about whether or not to tell patients about potential disease
causing genes in their genomes, as not only would affect them, but also relatives who could potentially carry the same genes themselves
[72,73]. Overall, the current consensus is that it is up to the individual researcher to decide how much information to pass on.
Validation is another important aspect to address in terms of using this technology for diagnosis and disease monitoring in a hospital
setting. As with any new diagnostic test, several questions need to be answered about its practicality and relevance within a clinical setting
as well as ensuring it can cope with that particular laboratory's workload, samples and turnaround times while providing data which is at
the same level, if not better, than the Gold Standard. In regards to NGS technologies, there are many questions to be answered such as should
every target be validated, should accuracy and speciﬁcity for every target for every sample type be validated, should the bioinformatics side
of this technology also be validated. The need to establish clear international validation guidelines has been clearly identiﬁed [74]. These
suggested guidelines would address the multiple validation questions raised by such an encompassing technology as well as provide advice
on how to make NGS as cost effective as possible in a clinical setting. This need for harmonization also emphasizes the need for a more in
depth discussion amongst clinical bodies to ensure NGS can be brought into the clinical setting sooner rather than later due its ability to
lower the complexity of the level tests required for particular haematological conditions currently required.
With the technology rapidly evolving to eliminate these challenges, and our better understanding of it in the research and diagnostic
settings, the massively parallel sequencing technology has already become the true gold-standards in many centres.
2. Conclusion
Since the completion of the Human Genome Project, the true potential in genetic research was truly realised beginning the development
and advancement of next generation sequencing technologies. This ﬁeld has grown at an exponential rate with multiple new companies
emerging dedicating their services to the ﬁeld, as well as many well established scientiﬁc companies developing their own technologies
[19,75]. The growth and dominance of this set of technologies has caused a shift in the framework of scientiﬁc research, opening the doors to
a new era of oncology research and diagnostics, as well as requiring scientists with stronger molecular knowledge alongside computational
skills to be able to carry out this work.
As the importance of this technology has been realised, research using thesemachines boomedwithmanymajor breakthroughs within a
short few years, as outlined in this review, but also in other areas such as that of sequencing ancient DNAwhich could potentially open the
doors to full high quality genome sequencing from a single cell, a development which could have major implications for diagnostic testing
[76], an area where this technology has been heavily validated for future use due to its vast array of uses, robustness, sensitivity, accuracy,
minimal DNA input, speed and information output. One such development in NGS with clinical implications in mind is that of amplicon
sequencing allowing for targeted sequencing of genes of interest to minimise data output and provide fast, expansive results on multiple
genes for particular disease to allow for a more comprehensive understanding of that patient and their clinical progress [68]. With the quick
advances in the speed, accuracy, and cost of these systems, the potential for using NGS as a clinical tool has become more feasible over the
last three years, supported by the multitude of validation research papers available today.
Overall, we have been challenged in our research by NGS with its ever evolving protocols, chemistry, and machinery with scientists
playing a game of catch up to keep up to datewith the technology but despite this, our understanding of the underlying genetic mechanisms
of many diseases both within and outside of haematology has proved NGS to be an essential tool in modern research and diagnostics.
Conﬂict of interest
None.
Abbreviations
PGM personal genome machine
FISH ﬂuorescence in situ hybridization
NGS next generation sequencing
GEP gene expression proﬁling
WGS whole genome sequencing
SNP single nucleotide polymorphisms
WES whole exome sequencing
FAB French/American/British Subtype
PCR polymerase chain reaction
SNVs single nucleotide variants
DNA deoxyribonucleic acid
mRNA messenger ribonucleic acid
RNA ribonucleic acid
CLL chronic lymphocytic leukaemia
CML chronic myeloid leukaemia
ALL acute lymphocytic leukaemia
AML acute myeloid leukaemia
CNA copy number analysis
DLBCL diffuse large B-cell leukaemia
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